showed that Berbamine (BBM), a marketing drug for treatment of leukopenia in China, obviously inhibited the activity of RAB8A GTPase in an obesity mouse model [56], indicating the variable activity of RAB8A in different diseases. This evidence concerns the gene RAB8A and obesity due to melanocortin 4 receptor deficiency.